Table 1 Frequency of breakthrough infection during observation period
| Â | n | Frequency | 95% CI (%) |
|---|---|---|---|
All patients | 9417 | 105 (1.1%) | 0.9–1.4 |
BNT162b2 (2 doses) | 6423 | 78 (1.2%) | 1.0–1.5 |
mRNA-1273 (2 doses) | 2993 | 27 (0.9%) | 0.6–1.3 |
Solid tumor malignancy | 6948 | 68 (1.0%) | 0.8–1.2 |
Hematologic malignancy | 1567 | 25 (1.6%) | 1.0–2.4 |